About The Study: In this meta-analysis, nirsevimab was associated with reduced lower respiratory tract infection-related hospitalizations and emergency department visits in infants and young children. These findings support nirsevimab’s potential to reduce respiratory-related morbidity in young children and health care utilization.
Corresponding Author: To contact the corresponding author, Seyed M. Moghadas, PhD, email moghadas@yorku.ca .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2025.5280)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.5280?guestAccessKey=9b006351-5935-47cc-935b-80764f884542&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122225
JAMA Pediatrics